Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 3/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291997 | 1.00 | BRD4 (0.47) | BRD4ATAD2OPRM1ALDH1A1ALOX15 | |
| SCHEMBL1053495 | 0.92 | JAK1 (0.49) | OPRM1ALDH1A1ALOX15CNR1CHEK1 | |
| SCHEMBL4295570 | 0.92 | OPRM1 (0.51) | BRD4ATAD2OPRM1ALDH1A1ALOX15 | |
| SCHEMBL1055073 | 0.77 | OPRM1 (0.61) | BRD4OPRM1ALDH1A1ALOX15CNR1 | |
| SCHEMBL1055067 | 0.75 | OPRM1 (0.57) | OPRM1ALDH1A1ALOX15CNR1CYP1A2 | |
| SCHEMBL1054942 | 0.75 | PDGFRB (0.52) | BRD4ATAD2ALDH1A1ALOX15CHEK1 | |
| SCHEMBL6208417 | 0.75 | CNR1 (0.61) | CNR1CHEK1 | |
| SCHEMBL1052650 | 0.74 | UTS2R (0.47) | BRD4ATAD2ALDH1A1ALOX15 | |
| SCHEMBL4309421 | 0.73 | CNR1 (0.58) | OPRM1CNR1KDM4EJAK1MAPK1 | |
| SCHEMBL13680299 | 0.72 | AURKA (0.54) | BRD4ATAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875624-B2 | administering a cancer patient 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one in the treatment of disorders relating to cell adhesion and metastatic processes; for monitoring the effects of drug by measuring the levels of ICAM, VCAM, or E-selectin in the patient | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | CHIRON CORPORATION | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | BRD4 697/4885ATAD2 2615/4885OPRM1 2790/4885 |
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | VCAM1, EPCAM, ICAM1 | BRD4 2641/4885ATAD2 4534/4885OPRM1 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.